Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test.

OBJECTIVES The overnight dexamethasone (DXM) suppression test (DST) has high sensitivity, but moderate specificity, for diagnosing hypercortisolism. We have evaluated if simultaneous measurement of S-DXM may correct for variable DXM bioavailability and increase the diagnostic performance of DST, and if saliva (sa) is a feasible adjunct or alternative to serum. DESIGN AND METHODS Prospective study of DST was carried out in patients with suspected Cushing's syndrome (CS) (n = 49), incidentaloma (n = 152) and healthy controls (n = 101). Cortisol, cortisone and DXM were assayed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). RESULTS Three hundred and two subjects underwent DST; S-cortisol was ≥50 nmol/L in 83 patients, of whom 11 had CS and 27 had autonomous cortisol secretion. The lower 2.5 percentile of S-DXM in subjects with negative DST (n = 208) was 3.3 nmol/L, which was selected as the DXM cut-off level. Nine patients had the combination of low S-DXM and positive DST. Of these, three had been misdiagnosed as having autonomous cortisol secretion. DST results were highly reproducible and confirmed in a replication cohort (n = 58). Patients with overt CS had significantly elevated post-DST sa-cortisol and sa-cortisone levels compared with controls; 23 of 25 with autonomous cortisol secretion had elevated sa-cortisone and 14 had elevated sa-cortisol. CONCLUSIONS Simultaneous measurement of serum DXM and cortisol reduced false-positive DSTs by 20% and improved the specificity. S-DXM >3.3 nmol/L is sufficient for the suppression of cortisol <50 nmol/L. Measurement of glucocorticoids in saliva is a non-invasive and easy procedure and post-DST sa-cortisone was found particularly useful in the diagnosis of CS.

[1]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[2]  F. Pecori Giraldi,et al.  Variability in laboratory parameters used for management of Cushing’s syndrome , 2015, Endocrine.

[3]  M. Hutz,et al.  Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians , 2014, Molecular Biology Reports.

[4]  E. Husebye,et al.  Multisteroid LC–MS/MS assay for glucocorticoids and androgens and its application in Addison's disease , 2013, Endocrine connections.

[5]  Luca Manetti,et al.  Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. , 2013, European journal of endocrinology.

[6]  B. Åsvold,et al.  Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test , 2012, Endocrine connections.

[7]  E. Papini,et al.  AME position statement on adrenal incidentaloma. , 2011, European journal of endocrinology.

[8]  G. Brabant,et al.  Measurement of salivary cortisol with liquid chromatography‐tandem mass spectrometry in patients undergoing dynamic endocrine testing , 2010, Clinical endocrinology.

[9]  D. Ray,et al.  Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  P. Wood,et al.  Salivary steroid assays – research or routine? , 2009, Annals of clinical biochemistry.

[11]  Ferruccio Ceriotti,et al.  Reference intervals: the way forward , 2009, Annals of clinical biochemistry.

[12]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  W. D. Johnson,et al.  Intraclass Correlation Coefficient , 2006, International Encyclopedia of Statistical Science.

[14]  S. Tsagarakis,et al.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications , 2006, Journal of endocrinological investigation.

[15]  P. Stokes,et al.  Hypercortisolemia decreases dexamethasone half-life in rabbit. , 2002, Journal of psychiatric research.

[16]  Wifredo Ricart,et al.  Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: a population study. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[18]  P. Björntorp,et al.  Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. , 1996, Obesity research.

[19]  J. O'Brien,et al.  Cortisol suppression by dexamethasone in the healthy elderly: Effects of age, dexamethasone levels, and cognitive function , 1994, Biological Psychiatry.

[20]  P. Meulenberg,et al.  The effect of oral contraceptive use and pregnancy on the daily rhythm of cortisol and cortisone. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[21]  G. Read,et al.  The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia , 1989, European Journal of Clinical Pharmacology.

[22]  T. Nickelsen,et al.  The Dexamethasone Suppression Test and Long-Term Contraceptive Treatment: Measurement of ACTH or Salivary Cortisol Does Not Improve the Reliability of the Test , 1989, Experimental and clinical endocrinology.

[23]  T. Benraad,et al.  The effect of oral contraceptives on plasma-free and salivary cortisol and cortisone. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[24]  H. D’haenen,et al.  Age and gender effects on the diagnostic power of the DST. , 1987, Journal of affective disorders.

[25]  W. Vaughn,et al.  Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. , 1986, The Journal of clinical endocrinology and metabolism.

[26]  Y. Ichikawa,et al.  Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. , 1985, The Journal of clinical endocrinology and metabolism.

[27]  A. Schatzberg,et al.  The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. , 1984, The American journal of psychiatry.

[28]  A. Meikle DEXAMETHASONE SUPPRESSION TESTS: USEFULNESS OF SIMULTANEOUS MEASUREMENT OF PLASMA CORTISOL AND DEXAMETHASONE , 1982, Clinical endocrinology.

[29]  W. Jusko,et al.  Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[30]  S. Brooks,et al.  The Effects of Ephedrine and Theophylline on Dexamethasone Metabolism in Bronchial Asthma , 1977, Journal of clinical pharmacology.

[31]  F. H. Tyler,et al.  Apparently normal pituitary-adrenal suppressibility in Cushing's syndrome: dexamethasone metabolism and plasma levels. , 1975, The Journal of laboratory and clinical medicine.

[32]  C. Ditzler,et al.  Bioavailability of oral dexamethasone , 1975, Clinical pharmacology and therapeutics.

[33]  R. L. Eddy,et al.  Cushing's syndrome: a prospective study of diagnostic methods. , 1973, The American journal of medicine.

[34]  S. Brooks,et al.  Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. , 1972, The New England journal of medicine.

[35]  A. H. Reed,et al.  Influence of statistical method used on the resulting estimate of normal range. , 1971, Clinical chemistry.

[36]  S. Symchowicz,et al.  Plasma binding of betamethasone-3H, dexamethasone-3H, and cortisol-14C--a comparative study. , 1969, Biochemical pharmacology.

[37]  J. Tucci,et al.  Rapid dexamethasone suppression test for Cushing's syndrome. , 1967, JAMA.

[38]  P. Tanswell,et al.  Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction , 2004, European Journal of Clinical Pharmacology.

[39]  S. Guthrie The impact of dexamethasone pharmacokinetics on the DST: a review. , 1991, Psychopharmacology bulletin.

[40]  M. Weiner Age and cortisol suppression by dexamethasone in normal subjects. , 1989, Journal of psychiatric research.

[41]  E. Werk,et al.  Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. , 1972, The Journal of clinical endocrinology and metabolism.